Affimed (AFMD) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

AFMD Stock Forecast

Affimed stock forecast is as follows: an average price target of $7.50 (represents a 532.91% upside from AFMD’s last price of $1.19) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

AFMD Price Target

The average price target for Affimed (AFMD) is $7.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $5.00. This represents a potential 532.91% upside from AFMD's last price of $1.19.

AFMD Analyst Ratings

Buy

According to 5 Wall Street analysts, Affimed's rating consensus is 'Buy'. The analyst rating breakdown for AFMD stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Affimed Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Apr 01, 2024	Bradley Canino	Stifel Nicolaus	$5.00	$5.30	-5.66%	321.94%
Apr 01, 2024	Swayampakula Ramakanth	H.C. Wainwright	$10.00	$5.30	88.68%	743.88%

The latest Affimed stock forecast, released on Apr 01, 2024 by Bradley Canino from Stifel Nicolaus, set a price target of $5.00, which represents a -5.66% decrease from the stock price at the time of the forecast ($5.30), and a 321.94% increase from AFMD last price ($1.19).

Affimed Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$7.50
Last Closing Price	$1.19	$1.19	$1.19
Upside/Downside	-100.00%	-100.00%	532.91%

In the current month, the average price target of Affimed stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Affimed's last price of $1.19. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 15, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 12, 2024	Laidlaw	Buy	Buy	Hold
Apr 01, 2024	H.C. Wainwright	Buy	Buy	Hold
Dec 12, 2022	H.C. Wainwright		Buy	Initialise
Oct 11, 2022	Stifel Nicolaus		Positive	Downgrade
Mar 31, 2022	Piper Sandler		Overweight	Initialise
Feb 23, 2022	Cantor Fitzgerald		Overweight	Initialise

Affimed's last stock rating was published by H.C. Wainwright on Nov 15, 2024. The company gave AFMD a "Buy" rating, the same as its previous rate.

Affimed Financial Forecast

Affimed Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$4.51M	$11.16M	$14.89M	$7.30M	$8.01M	$10.34M	$8.66M	$9.71M	$11.66M	$9.75M	$10.54M	$2.93M	$5.13M	$3.93M	$2.10M
Avg Forecast	$151.48K	$151.73K	$151.98K	$152.23K	$353.26K	$423.91K	$423.91K	$1.45M	$1.08M	$1.67M	$1.16M	$458.57K	$1.66M	$1.93M	$4.65M	$6.16M	$6.92M	$6.29M	$8.83M	$10.31M	$8.98M	$9.59M	$9.01M	$10.63M	$16.63M	$8.79M	$5.20M	$5.47M	$3.09M	$3.71M
High Forecast	$267.66K	$268.10K	$268.54K	$268.99K	$624.20K	$749.04K	$749.04K	$3.29M	$1.46M	$2.95M	$2.05M	$810.29K	$2.62M	$3.41M	$8.22M	$10.89M	$12.23M	$6.29M	$8.83M	$10.31M	$8.98M	$9.59M	$9.01M	$10.63M	$16.63M	$8.79M	$5.20M	$5.47M	$3.09M	$3.71M
Low Forecast	$78.10K	$78.23K	$78.36K	$78.49K	$182.14K	$218.57K	$218.57K	$529.89K	$688.00K	$861.13K	$597.58K	$236.45K	$643.08K	$995.10K	$2.40M	$3.18M	$3.57M	$6.29M	$8.83M	$10.31M	$8.98M	$9.59M	$9.01M	$10.63M	$16.63M	$8.79M	$5.20M	$5.47M	$3.09M	$3.71M
# Analysts	1	1	1	1	1	1	1	3	3	2	2	2	5	2	2	2	1	1	1	1	2	2	2	2	11	8	8	12	7	12
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.73%	1.61%	2.37%	0.83%	0.78%	1.15%	0.90%	1.08%	1.10%	0.59%	1.20%	0.56%	0.94%	1.27%	0.57%

Affimed's average Quarter revenue forecast for Jun 23 based on 2 analysts is $4.65M, with a low forecast of $2.40M, and a high forecast of $8.22M. AFMD's average Quarter revenue forecast represents a 3.18% increase compared to the company's last Quarter revenue of $4.51M (Mar 23).

Affimed EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	3	2	2	2	5	2	2	2	1	1	1	1	2	2	2	2	11	8	8	12	7	12
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-30.66M	$-27.85M	$-18.73M	$-21.33M	$-16.85M	$-22.51M	$-16.56M	$-18.24M	$1.83M	$-14.66M	$-5.65M	$-11.90M	$-7.95M	$-12.64M	$-10.55M
Avg Forecast	$-151.48K	$-151.73K	$-151.98K	$-152.23K	$-353.26K	$-423.91K	$-423.91K	$-1.45M	$-1.08M	$-1.67M	$-1.16M	$-458.57K	$-1.66M	$-1.93M	$-4.65M	$-6.16M	$-6.92M	$-6.29M	$-8.83M	$-10.31M	$-8.98M	$-9.59M	$-9.01M	$3.71M	$-16.63M	$-8.79M	$-5.20M	$-7.95M	$-3.09M	$-3.71M
High Forecast	$-78.10K	$-78.23K	$-78.36K	$-78.49K	$-182.14K	$-218.57K	$-218.57K	$-529.89K	$-688.00K	$-861.13K	$-597.58K	$-236.45K	$-643.08K	$-995.10K	$-2.40M	$-3.18M	$-3.57M	$-6.29M	$-8.83M	$-10.31M	$-8.98M	$-9.59M	$-9.01M	$4.45M	$-16.63M	$-8.79M	$-5.20M	$-6.36M	$-3.09M	$-3.71M
Low Forecast	$-267.66K	$-268.10K	$-268.54K	$-268.99K	$-624.20K	$-749.04K	$-749.04K	$-3.29M	$-1.46M	$-2.95M	$-2.05M	$-810.29K	$-2.62M	$-3.41M	$-8.22M	$-10.89M	$-12.23M	$-6.29M	$-8.83M	$-10.31M	$-8.98M	$-9.59M	$-9.01M	$2.96M	$-16.63M	$-8.79M	$-5.20M	$-9.53M	$-3.09M	$-3.71M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.97%	4.03%	2.98%	2.42%	1.63%	2.51%	1.73%	2.02%	0.49%	0.88%	0.64%	2.29%	1.00%	4.09%	2.85%

2 analysts predict AFMD's average Quarter EBITDA for Jun 21 to be $-9.01M, with a high of $-9.01M and a low of $-9.01M. This is -592.55% lower than Affimed's previous annual EBITDA (Mar 21) of $1.83M.

Affimed Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	3	2	2	2	5	2	2	2	1	1	1	1	2	2	2	2	11	8	8	12	7	12
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-31.98M	$-36.73M	$-13.77M	$-17.16M	$-16.66M	$-23.27M	$-17.09M	$-18.75M	$1.41M	$-14.87M	$-5.97M	$-12.24M	$-8.29M	$-12.99M	$-10.88M
Avg Forecast	$-10.15M	$-10.17M	$-8.74M	$-8.76M	$-9.08M	$-8.90M	$-8.28M	$-8.21M	$-10.26M	$-14.08M	$-14.80M	$-23.76M	$-23.64M	$-28.26M	$-28.60M	$-29.22M	$-29.11M	$-26.55M	$-25.57M	$-26.95M	$-24.51M	$-21.42M	$-13.11M	$2.86M	$-2.27M	$-12.58M	$-20.23M	$-8.29M	$-27.32M	$-27.44M
High Forecast	$-3.76M	$-3.77M	$-3.24M	$-3.25M	$-3.36M	$-3.29M	$-3.07M	$-7.58M	$-5.93M	$-5.21M	$-5.48M	$-8.80M	$-17.84M	$-10.46M	$-10.59M	$-10.82M	$-10.78M	$-26.55M	$-25.57M	$-26.95M	$-24.51M	$-21.42M	$-13.11M	$3.43M	$-2.27M	$-12.58M	$-20.23M	$-6.63M	$-27.32M	$-27.44M
Low Forecast	$-20.27M	$-20.32M	$-17.46M	$-17.50M	$-18.14M	$-17.77M	$-16.54M	$-8.84M	$-15.76M	$-28.12M	$-29.55M	$-47.45M	$-30.63M	$-56.44M	$-57.11M	$-58.35M	$-58.14M	$-26.55M	$-25.57M	$-26.95M	$-24.51M	$-21.42M	$-13.11M	$2.29M	$-2.27M	$-12.58M	$-20.23M	$-9.95M	$-27.32M	$-27.44M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.09%	1.26%	0.52%	0.67%	0.62%	0.95%	0.80%	1.43%	0.49%	6.54%	0.47%	0.61%	1.00%	0.48%	0.40%

Affimed's average Quarter net income forecast for Jun 21 is $-13.11M, with a range of $-13.11M to $-13.11M. AFMD's average Quarter net income forecast represents a -1028.18% decrease compared to the company's last Quarter net income of $1.41M (Mar 21).

Affimed SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	3	2	2	2	5	2	2	2	1	1	1	1	2	2	2	2	11	8	8	12	7	12
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$6.85M	$8.57M	$8.09M	$8.37M	$7.04M	$7.45M	$6.84M	$5.44M	$4.49M	$4.13M	$3.46M	$2.61M	$3.52M	$2.70M	$2.79M
Avg Forecast	$161.20K	$161.47K	$161.74K	$162.00K	$375.93K	$451.12K	$451.12K	$1.54M	$1.15M	$1.78M	$1.23M	$488.01K	$1.76M	$2.05M	$4.95M	$6.56M	$7.36M	$6.70M	$9.39M	$10.97M	$9.56M	$10.21M	$9.59M	$9.08M	$17.69M	$9.36M	$5.54M	$3.52M	$3.29M	$3.94M
High Forecast	$284.84K	$285.31K	$285.78K	$286.25K	$664.26K	$797.12K	$797.12K	$3.50M	$1.55M	$3.14M	$2.18M	$862.30K	$2.79M	$3.63M	$8.75M	$11.59M	$13.01M	$6.70M	$9.39M	$10.97M	$9.56M	$10.21M	$9.59M	$10.90M	$17.69M	$9.36M	$5.54M	$4.23M	$3.29M	$3.94M
Low Forecast	$83.12K	$83.25K	$83.39K	$83.53K	$193.84K	$232.60K	$232.60K	$563.90K	$732.17K	$916.41K	$635.94K	$251.62K	$684.36K	$1.06M	$2.55M	$3.38M	$3.80M	$6.70M	$9.39M	$10.97M	$9.56M	$10.21M	$9.59M	$7.27M	$17.69M	$9.36M	$5.54M	$2.82M	$3.29M	$3.94M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.04%	1.16%	1.21%	0.89%	0.64%	0.78%	0.67%	0.57%	0.49%	0.23%	0.37%	0.47%	1.00%	0.82%	0.71%

Affimed's average Quarter SG&A projection for Jun 23 is $4.95M, based on 2 Wall Street analysts, with a range of $2.55M to $8.75M. The forecast indicates a -27.71% fall compared to AFMD last annual SG&A of $6.85M (Mar 23).

Affimed EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	3	2	2	2	5	2	2	2	1	1	1	1	2	2	2	2	11	8	8	12	7	12
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.21	$-0.26	$-0.09	$-0.12	$-0.14	$-0.29	$-0.14	$-0.16	$0.01	$-0.13	$-0.07	$-0.16	$-0.11	$-0.17	$-0.17
Avg Forecast	$-0.66	$-0.66	$-0.57	$-0.57	$-0.59	$-0.58	$-0.54	$-0.54	$-0.67	$-0.92	$-0.97	$-1.55	$-1.55	$-1.85	$-1.87	$-1.91	$-1.90	$-1.74	$-1.67	$-1.76	$-1.60	$-1.40	$-0.86	$-1.00	$-0.15	$-0.82	$-1.32	$-1.29	$-1.79	$-1.79
High Forecast	$-0.25	$-0.25	$-0.21	$-0.21	$-0.22	$-0.22	$-0.20	$-0.50	$-0.39	$-0.34	$-0.36	$-0.58	$-1.17	$-0.68	$-0.69	$-0.71	$-0.70	$-1.74	$-1.67	$-1.76	$-1.60	$-1.40	$-0.86	$-1.00	$-0.15	$-0.82	$-1.32	$-1.29	$-1.79	$-1.79
Low Forecast	$-1.32	$-1.33	$-1.14	$-1.14	$-1.19	$-1.16	$-1.08	$-0.58	$-1.03	$-1.84	$-1.93	$-3.10	$-2.00	$-3.69	$-3.73	$-3.81	$-3.80	$-1.74	$-1.67	$-1.76	$-1.60	$-1.40	$-0.86	$-1.00	$-0.15	$-0.82	$-1.32	$-1.29	$-1.79	$-1.79
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.11%	0.14%	0.05%	0.07%	0.08%	0.18%	0.10%	0.19%	-0.01%	0.86%	0.09%	0.12%	0.09%	0.10%	0.09%

According to 2 Wall Street analysts, Affimed's projected average Quarter EPS for Jun 21 is $-0.86, with a low estimate of $-0.86 and a high estimate of $-0.86. This represents a -8665.40% decrease compared to AFMD previous annual EPS of $0.01 (Mar 21).

Affimed Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.52	$70.00	13361.54%	Buy
ELEV	Elevation Oncology	$0.67	$9.00	1243.28%	Buy
ADAP	Adaptimmune Therapeutics	$0.60	$4.00	566.67%	Buy
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
AFMD	Affimed	$1.51	$7.50	396.69%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
PDSB	PDS Bio	$1.96	$9.00	359.18%	Buy
ADCT	ADC Therapeutics SA	$2.13	$9.33	338.03%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
AGEN	Agenus	$2.96	$7.33	147.64%	Hold
MREO	Mereo BioPharma Group	$3.40	$8.00	135.29%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
LPTX	Leap Therapeutics	$3.11	$5.50	76.85%	Buy
CRVS	Corvus Pharmaceuticals	$7.39	$12.50	69.15%	Buy

AFMD Forecast FAQ

Is Affimed a good buy?

Yes, according to 5 Wall Street analysts, Affimed (AFMD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of AFMD's total ratings.

What is AFMD's price target?

Affimed (AFMD) average price target is $7.5 with a range of $5 to $10, implying a 532.91% from its last price of $1.19. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Affimed stock go up soon?

According to Wall Street analysts' prediction for AFMD stock, the company can go up by 532.91% (from the last price of $1.19 to the average price target of $7.5), up by 743.88% based on the highest stock price target, and up by 321.94% based on the lowest stock price target.

Can Affimed stock reach $2?

AFMD's average twelve months analyst stock price target of $7.5 supports the claim that Affimed can reach $2 in the near future.

What are Affimed's analysts' financial forecasts?

Affimed's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.65M (high $5.41M, low $1.15M), average EBITDA is $-2.649M (high $-1.149M, low $-5.408M), average net income is $-34.472M (high $-17.303M, low $-61.289M), average SG&A $2.82M (high $5.75M, low $1.22M), and average EPS is $-2.253 (high $-1.131, low $-4.006). AFMD's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $607.42K (high $1.07M, low $313.19K), average EBITDA is $-607K (high $-313K, low $-1.073M), average net income is $-37.83M (high $-14.008M, low $-75.548M), average SG&A $646.41K (high $1.14M, low $333.29K), and average EPS is $-2.472 (high $-0.916, low $-4.937).

Did the AFMD's actual financial results beat the analysts' financial forecasts?

Based on Affimed's last annual report (Dec 2022), the company's revenue was $41.35M, beating the average analysts forecast of $32.35M by 27.84%. Apple's EBITDA was $-86.637M, beating the average prediction of $-32.346M by 167.84%. The company's net income was $-86.004M, missing the average estimation of $-108M by -20.50%. Apple's SG&A was $32.08M, missing the average forecast of $34.42M by -6.82%. Lastly, the company's EPS was $-0.6, missing the average prediction of $-7.07 by -91.51%. In terms of the last quarterly report (Mar 2023), Affimed's revenue was $4.51M, missing the average analysts' forecast of $6.16M by -26.82%. The company's EBITDA was $-30.662M, beating the average prediction of $-6.163M by 397.50%. Affimed's net income was $-31.983M, beating the average estimation of $-29.218M by 9.46%. The company's SG&A was $6.85M, beating the average forecast of $6.56M by 4.44%. Lastly, the company's EPS was $-0.21, missing the average prediction of $-1.91 by -89.00%